Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Accumulated Depreciation (2020 - 2025)

SAB Biotherapeutics' Accumulated Depreciation history spans 6 years, with the latest figure at $17.5 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation rose 20.19% year-over-year to $17.5 million; the TTM value through Dec 2025 reached $17.5 million, up 20.19%, while the annual FY2025 figure was $17.5 million, 20.19% up from the prior year.
  • Accumulated Depreciation reached $17.5 million in Q4 2025 per SABSW's latest filing, up from $16.8 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $17.5 million in Q4 2025 to a low of $3.2 million in Q4 2021.
  • Average Accumulated Depreciation over 5 years is $10.7 million, with a median of $11.9 million recorded in 2024.
  • Peak YoY movement for Accumulated Depreciation: skyrocketed 94.98% in 2022, then rose 20.19% in 2025.
  • A 5-year view of Accumulated Depreciation shows it stood at $3.2 million in 2021, then soared by 94.98% to $6.3 million in 2022, then skyrocketed by 57.87% to $9.9 million in 2023, then soared by 47.04% to $14.6 million in 2024, then rose by 20.19% to $17.5 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Accumulated Depreciation are $17.5 million (Q4 2025), $16.8 million (Q3 2025), and $16.1 million (Q2 2025).